Clinical Trial Update: A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the efficacy and safety of the PET tracer [18F]NAV4694 for detecting cerebral beta-amyloid, using postmortem histopathology …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• [18F]NAV4694 (NAV4694)

Snippet

Sponsor: Navidea Biopharmaceuticals | Conditions: Dementia, Alzheimer's Disease | Phase 3 | Status: UNKNOWN